Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
CONCLUSIONS: The results of the studies suggest that a prandial GLP-1 RA as an add-on to basal insulin may be a safe and effective treatment intensification option (vs basal-plus or basal-bolus insulin).
PMID: 28836861 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Canada Health | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Insulin | Research | Study | Weight Loss